Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma Stocks in red
Tue, 21 Apr 01:30 pm

Indian markets are trading with a negative bias as yesterday's sell-off continued. Indian benchmarks BSE-Sensex and NSE-Nifty are trading sideways in the post noon session. Today, all the sectors are trading marginally in the green, with realty sector witnessing maximum buying interest. However, Healthcare stocks witnessed maximum selling pressure led by losses in Sun Pharma, Dr Reddy and Cipla.

The BSE-Sensex is trading down by 10 points while the NSE-Nifty is down by around 3 points. S&P BSE Midcap and S&P BSE Smallcap are trading up by 0.5% and 0.25%, respectively. The rupee is trading at Rs 62.92 to the US dollar.

According to a leading financial daily, shares of Sun Pharmaceutical Industries have tanked 9% to Rs 950 after Japanese pharmaceuticals company Daiichi Sankyo sold its stake in the company via an open market transaction. Daiichi Sankyo put 8.9% stake, approximately 215 million shares on the block. Reportedly, the promoter Dilip Sanghvi is likely to pick up part of the 9% stake on offer. Sun Pharma has fallen to lowest level since March 3 post Daiichi stake sale.

Engineering stocks are trading on a mixed note today. Crompton Greaves and Honeywell Automation are the losers, while Voltas and Kalpataru Power are the largest gainers. According to a leading financial daily, state owned power equipment maker BHEL has commissioned a 250 MW coal based thermal power plant in Gujarat. The unit has been custom-built at the Gujarat State Electricity Corporation Ltd's (GSECL) Sikka thermal power station (TPS) by Bharat Heavy Electricals Ltd (BHEL), on engineering, procurement and construction basis. Reportedly, two units of 120 MW supplied and executed by BHEL are already in operation at Sikka and another 250 MW unit is in an advanced stage of commissioning. GSECL has recently entrusted BHEL with an order for setting up an 800 MW supercritical coal based project at Wanakbori in Gujarat.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma Stocks in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.